1. Adjuvant therapy versus watch-and-wait post surgery for stage III melanoma: a multicountry retrospective chart review
- Author
-
Rodrigo U Villarroel, Rama Koneru, Virtudes Soriano, Jonathan S. Zager, Roy Koruth, Olivier Dereure, Maurice Perrinjaquet, Karmele Mujika, Felix Kiecker, Eva Muñoz Couselo, Lisa A. Kottschade, Yana G. Najjar, Peter Mohr, Raluca Ionescu-Ittu, Matias Chacón, Philippe Saiag, Rebecca Burne, Jochen Utikal, Florencia Cuadros, Caroline Robert, and Annie Guerin more...
- Subjects
nodal disease ,medicine.medical_specialty ,medicine.medical_treatment ,Dermatology ,Post surgery ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Chart review ,melanoma ,medicine ,Adjuvant therapy ,Stage III melanoma ,In patient ,030212 general & internal medicine ,Adverse effect ,business.industry ,Melanoma ,adjuvant therapy ,interferon ,medicine.disease ,Oncology ,030220 oncology & carcinogenesis ,stage III melanoma ,business ,Adjuvant ,Research Article ,metastatic melanoma - Abstract
Aim: To describe treatment patterns among patients with stage III melanoma who underwent surgical excision in years 2011–2016, and assess outcomes among patients who subsequently received systemic adjuvant therapy versus watch-and-wait. Methods: Chart review of 380 patients from 17 melanoma centers in North America, South America and Europe. Results: Of 129 (34%) patients treated with adjuvant therapy, 85% received interferon α-2b and 56% discontinued treatment (mostly due to adverse events). Relapse-free survival was significantly longer for patients treated with adjuvant therapy versus watch-and-wait (hazard ratio = 0.63; p < 0.05). There was considerable heterogeneity in adjuvant treatment schedules and doses. Similar results were found in patients who received interferon-based adjuvant therapy. Conclusion: Adjuvant therapies with better safety/efficacy profiles will improve clinical outcomes in patients with stage III melanoma. more...
- Published
- 2019
- Full Text
- View/download PDF